Table 1 Efficacy of capmatinib in GEOMETRY mono-1
From: Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer
| Previously treated patients (n = 69) | |
| ORR (%) | 41 (95% CI: 29–53) |
| Medium DOR (months) | 9.7 (95% CI: 5.6–13.0) |
| Medium PFS (months) | 5.4 (95% CI: 5.4–7.0) |
| Treatment-naïve patients (n = 28) | |
| ORR (%) | 68 (95% CI: 48–84) |
| Medium DOR (months) | 12.6 (95% CI: 5.6–NE) |
| Medium PFS (months) | 12.4 (95% CI: 8.2–NE) |
| Patients with measurable CNS metastasis (n = 13) | |
| CR (%) | 31 |
| PR (%) | 23 |